A Phase 2 interventional study of Rotigotine Nasal Spray and Placebo Nasal Spray in Restless Legs Syndrome, sponsored by UCB Pharma. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-10-02.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing rotigotine in Restless Legs Syndrome — none open to participants now, none under way, none of them phase 3. rotigotine · Restless Legs Syndrome.
Among the 19 studies testing rotigotine in Restless Legs Syndrome, this one is the 13th largest by enrollment, is one of 2 that started in 2006, is one of 6 in phase 2, and was the 5th registered.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
Browse Restless Legs Syndrome studies →None of the 19 studies testing rotigotine in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2006.
This study's enrollment of 44 is below the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.
Median enrollment 130 across the 19 interventional studies. Of the 19 that completed or were terminated, 13 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 19 have an industry lead sponsor. The 7 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
17 studies in Restless Legs Syndrome by UCB S.A.: none open now, none under way, none of them phase 3. Of 17 finished, 11 (65%) have results posted.
Among the 17 studies in Restless Legs Syndrome by UCB S.A., this one is the 10th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2006, is one of 5 in phase 2, and was the 6th registered.
UCB S.A.’s Restless Legs Syndrome studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing rotigotine in Restless Legs Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 17 in Restless Legs Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objective of this phase 2a proof-of-concept trial is to assess the efficacy of rotigotine nasal spray in ascending doses in subjects with idiopathic Restless Legs Syndrome.
Each patient of the placebo and rotigotine group performed an Eligibility Assessment, as well 4 treatment days at which subjects performed a repeated 'Suggested Immobilization Test' (SIT) during a 30min pre-dose and a 4 hours post-dose period. During these periods the severity of RLS symptoms in the legs was assessed by the subject using a numeric symptom severity scale.
In addition the leg movements were measured by actigraphy to assess the Periodic Leg Movement Index during Wakefulness (PLMWI, PLM per hour). Subjects applied a single dose of treatment on each treatment day (placebo nasal spray or rotigotine nasal spray in 3 ascending doses).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects receiving a single dose of placebo nasal spray on all 4 treatment days
Other: Placebo Nasal Spray
Subjects receiving doses of placebo nasal spray on Day 1 or Day 2, Rotigotine nasal spray 62µg on Day 1 or Day 2, Rotigotine nasal spray 124µg on Day 3, and Rotigotine nasal spray 247µg on Day 4
Drug: Rotigotine Nasal Spray
Daily single dose of 62µg, 124µg, and 247µg rotigotine delivered as single puff of nasal spray solution
Also known as: SPM937
Daily single dose of placebo delivered as single puff of nasal spray solution
Average Numeric Symptom Severity Score After Single Dose of Rotigotine Nasal Spray or Matching Placebo
Subjects rate the severity of the RLS symptoms at the start of each pre dose and post dose Suggested Immobilization Test (SIT-0 to SIT-6) and every 5min during each SIT, using a numeric symptoms severity scale, where 0=not severe and 10=very severe.
Time frame: 4 hours post-treatment period at each treatment day
Average PLMWI (Periodic Leg Movement Index During Wakefulness) After Single Dose of Rotigotine Nasal Spray or Matching Placebo.
The Periodic Limb Movement (PLM) during Wakefulness Index (PLMWI) measures the number of limb movements per hour and indicates the frequency of PLMs when the subject is awake and the degree of motor symptoms of the disorder during wake time. No movements would result in a score of 0 PLM per hour. Outcome is the average movements per hour in the 4 hour post-dose period per subject.
Time frame: 4 hours post-treatment period at each treatment day
| Milestone | Placebo | Rotigotine Nasal Spray |
|---|---|---|
| Started | 10 | 34 |
| Completed | 10 | 27 |
| Not completed | 0 | 7 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Did not receive treatment. | 0 | 2 |
| Withdrew: Other reasons | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
Subjects rate the severity of the RLS symptoms at the start of each pre dose and post dose Suggested Immobilization Test (SIT-0 to SIT-6) and every 5min during each SIT, using a numeric symptoms severity scale, where 0=not severe and 10=very severe.
| score on a scale | Placebo - Day 1 | Placebo - Day 2 | Placebo - Day 3 | Placebo - Day 4 | Rotigotine Nasal Spray - Placebo | Rotigotine Nasal Spray - Rotigotine 62µg | Rotigotine Nasal Spray - Rotigotine 124µg | Rotigotine Nasal Spray - Rotigotine 247µg |
|---|---|---|---|---|---|---|---|---|
| Average Numeric Symptom Severity Score After Single Dose of Rotigotine Nasal Spray or Matching Placebo | 2.6 ± 1.76 | 2.2 ± 1.44 | 2.5 ± 2.03 | 2.0 ± 1.65 | 2.9 ± 1.99 | 2.7 ± 1.84 | 2.0 ± 1.14 | 1.5 ± 1.21 |
The Periodic Limb Movement (PLM) during Wakefulness Index (PLMWI) measures the number of limb movements per hour and indicates the frequency of PLMs when the subject is awake and the degree of motor symptoms of the disorder during wake time. No movements would result in a score of 0 PLM per hour. Outcome is the average movements per hour in the 4 hour post-dose period per subject.
| PLM per hour | Placebo - Day 1 | Placebo - Day 2 | Placebo - Day 3 | Placebo - Day 4 | Rotigotine Nasal Spray - Placebo | Rotigotine Nasal Spray - Rotigotine 62µg | Rotigotine Nasal Spray - Rotigotine 124µg | Rotigotine Nasal Spray - Rotigotine 247µg |
|---|---|---|---|---|---|---|---|---|
| Average PLMWI (Periodic Leg Movement Index During Wakefulness) After Single Dose of Rotigotine Nasal Spray or Matching Placebo. | 37.8 ± 35.10 | 22.6 ± 28.36 | 34.9 ± 39.78 | 19.0 ± 23.60 | 28.7 ± 29.91 | 25.4 ± 25.14 | 26.2 ± 22.78 | 20.2 ± 21.70 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo - Day 1 | — | 0/10 (0%) | 4/10 (40%) |
| Placebo - Day 2 | — | 0/10 (0%) | 3/10 (30%) |
| Placebo - Day 3 | — | 0/10 (0%) | 2/10 (20%) |
| Placebo - Day 4 | — | 0/10 (0%) | 2/10 (20%) |
| Rotigotine Nasal Spray - Placebo | — | 0/31 (0%) | 16/31 (51.6%) |
| Rotigotine Nasal Spray - Rotigotine 62µg | — | 0/31 (0%) | 14/31 (45.2%) |
| Rotigotine Nasal Spray - Rotigotine 124µg | — | 0/28 (0%) | 10/28 (35.7%) |
| Rotigotine Nasal Spray - Rotigotine 247µg | — | 0/28 (0%) | 11/28 (39.3%) |
| Event | Placebo - Day 1 | Placebo - Day 2 | Placebo - Day 3 | Placebo - Day 4 | Rotigotine Nasal Spray - Placebo | Rotigotine Nasal Spray - Rotigotine 62µg | Rotigotine Nasal Spray - Rotigotine 124µg | Rotigotine Nasal Spray - Rotigotine 247µg |
|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/10 | 2/10 | 0/10 | 2/10 | 9/31 | 5/31 | 3/28 | 3/28 |
| PalpitationsCardiac disorders | 0/10 | 1/10 | 0/10 | 0/10 | 0/31 | 0/31 | 1/28 | 0/28 |
| Eye irritationEye disorders | 0/10 | 0/10 | 1/10 | 0/10 | 0/31 | 0/31 | 1/28 | 0/28 |
| DiarrhoeaGastrointestinal disorders | 1/10 | 0/10 | 0/10 | 1/10 | 2/31 | 0/31 | 0/28 | 0/28 |
| Abdominal painGastrointestinal disorders | 0/10 | 0/10 | 0/10 | 1/10 | 0/31 | 0/31 | 0/28 | 0/28 |
| FatigueGeneral disorders | 1/10 | 0/10 | 0/10 | 0/10 | 1/31 | 1/31 | 1/28 | 0/28 |
| Neck painMusculoskeletal and connective tissue disorders | 0/10 | 1/10 | 0/10 | 0/10 | 0/31 | 0/31 | 0/28 | 0/28 |
| ParaesthesiaNervous system disorders | 0/10 | 0/10 | 1/10 | 0/10 | 0/31 | 0/31 | 0/28 | 0/28 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/10 | 0/10 | 1/10 | 0/10 | 1/31 | 0/31 | 0/28 | 0/28 |
| SneezingRespiratory, thoracic and mediastinal disorders | 0/10 | 0/10 | 1/10 | 0/10 | 0/31 | 0/31 | 0/28 | 0/28 |
| Age, Categorical(Participants) | Placebo | Rotigotine Nasal Spray | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 9 | 33 | 42 |
| >=65 years | 1 | 1 | 2 |
| Age, Continuous(years) | Placebo | Rotigotine Nasal Spray | Total |
|---|---|---|---|
| Mean | 55.5 ± 5.40 | 52.9 ± 7.78 | 53.5 ± 7.33 |
| Sex: Female, Male(Participants) | Placebo | Rotigotine Nasal Spray | Total |
|---|---|---|---|
| Female | 8 | 21 | 29 |
| Male | 2 | 13 | 15 |
| Region of Enrollment(participants) | Placebo | Rotigotine Nasal Spray | Total |
|---|---|---|---|
| Germany | 10 | 34 | 44 |
The record gives a start of Aug 2006, a primary completion of Nov 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2009, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine